Redefining Immuno-Oncology
Engineering a New Generation of Oncolytic Virus-Based Cancer Immunotherapies with AI-Powered Precision
Our AI-Driven Scientific Platform
At NucleoVir, we pioneer a revolutionary AI-powered approach to drug discovery. Our proprietary platform fuses advanced bioinformatics, generative AI, and machine learning to design and optimize novel biologic therapies with unmatched precision and velocity.
Target Identification
Harnessing multi-omics data and deep learning to unearth novel disease drivers and therapeutic targets.
Generative Design
Leveraging generative AI models to craft potent, specific biologic candidates de novo.
Validation & Acceleration
Propelling AI-designed therapeutics via in-silico simulations and experimental validation.
About NucleoVir
Founded by visionary scientists and engineers, NucleoVir Therapeutics is a Biotech Therapeutics startup committed to reshaping patient lives through AI-accelerated innovation.
Our Founders
Yogesh Ostwal PhD
Co-Founder & CEO
Ayush Ranawade PhD
Co-Founder & CSO
Sunil Kapgate PhD
Co-Founder & CTO